Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Orbital apocenter is not a sufficient condition for HST/STIS detection of Europa's water vapor aurora.

Roth L, Retherford KD, Saur J, Strobel DF, Feldman PD, McGrath MA, Nimmo F.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):E5123-32. doi: 10.1073/pnas.1416671111. Epub 2014 Nov 17.

2.

Transient water vapor at Europa's south pole.

Roth L, Saur J, Retherford KD, Strobel DF, Feldman PD, McGrath MA, Nimmo F.

Science. 2014 Jan 10;343(6167):171-4. doi: 10.1126/science.1247051. Epub 2013 Dec 12.

PMID:
24336567
3.

A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions.

Tanaka Y, Rohde LA, Jin L, Feldman PD, Upadhyaya HP.

J Child Adolesc Psychopharmacol. 2013 May;23(4):262-70. doi: 10.1089/cap.2012.0049.

PMID:
23683141
4.

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.

Ascher-Svanum H, Montgomery WS, McDonnell DP, Coleman KA, Feldman PD.

Int J Gen Med. 2012;5:391-8. doi: 10.2147/IJGM.S29052. Epub 2012 May 4.

5.

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia.

Ascher-Svanum H, Brnabic AJ, Lawson AH, Kinon BJ, Stauffer VL, Feldman PD, Kelin K.

Neuropsychiatr Dis Treat. 2012;8:113-8. doi: 10.2147/NDT.S30268. Epub 2012 Mar 15.

6.

Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.

Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR.

Schizophr Res. 2012 Feb;134(2-3):195-201. doi: 10.1016/j.schres.2011.09.028. Epub 2011 Oct 21.

PMID:
22019076
7.

Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.

McDonnell DP, Kryzhanovskaya LA, Zhao F, Detke HC, Feldman PD.

Hum Psychopharmacol. 2011 Aug;26(6):422-33. doi: 10.1002/hup.1225. Epub 2011 Aug 5. Erratum in: Hum Psychopharmacol. 2011 Oct;26(7):536.

PMID:
21823172
8.

Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.

Liu-Seifert H, Osuntokun OO, Feldman PD.

Compr Psychiatry. 2012 Jan;53(1):107-15. doi: 10.1016/j.comppsych.2010.12.003. Epub 2011 Feb 9.

PMID:
21310400
9.

Patient perspectives on antipsychotic treatments and their association with clinical outcomes.

Liu-Seifert H, Osuntokun OO, Godfrey JL, Feldman PD.

Patient Prefer Adherence. 2010 Oct 5;4:369-77.

10.

LRO-LAMP observations of the LCROSS impact plume.

Gladstone GR, Hurley DM, Retherford KD, Feldman PD, Pryor WR, Chaufray JY, Versteeg M, Greathouse TK, Steffl AJ, Throop H, Parker JW, Kaufmann DE, Egan AF, Davis MW, Slater DC, Mukherjee J, Miles PF, Hendrix AR, Colaprete A, Stern SA.

Science. 2010 Oct 22;330(6003):472-6. doi: 10.1126/science.1186474. Erratum in: Science. 2011 Sep 23;333(6050):1703.

11.

Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.

Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD.

Am J Geriatr Psychiatry. 2009 Sep;17(9):752-9. doi: 10.1097/JGP.0b013e3181aad585.

PMID:
19700948
12.

Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.

Buitelaar JK, Wilens TE, Zhang S, Ning Y, Feldman PD.

J Child Psychol Psychiatry. 2009 Mar;50(3):335-42. doi: 10.1111/j.1469-7610.2008.01960.x.

PMID:
19309330
13.

Ultraviolet groove efficiency of a holographic grating: implications for a dual-order spectrograph.

McCandliss SR, Burgh EB, Feldman PD.

Appl Opt. 2001 Jun 1;40(16):2626-31.

PMID:
18357277
14.

Narcissistic Ghosts in Rowland-Mounted, Concave Gratings with nu = 0 degrees : a Cautionary Note.

McCandliss SR, McPhate JB, Feldman PD.

Appl Opt. 1998 Aug 1;37(22):5070-4.

PMID:
18285977
15.

Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.

Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, Bailey CE, Dunn DW, Geller DA, Casat CD, Lipetz RS, Jain R, Newcorn JH, Ruff DD, Feldman PD, Furr AJ, Allen AJ.

J Child Adolesc Psychopharmacol. 2007 Oct;17(5):689-700.

PMID:
17979588
16.

Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.

Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard HL, Allen AJ, Milton DR, Feldman PD, Kelsey DK, Geller DA, Linder SL, Lewis DW, Winner PK, Kurlan RM, Mintz M.

J Atten Disord. 2008 Jan;11(4):470-81. Epub 2007 Oct 12.

PMID:
17934184
17.

CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.

Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW, Buitelaar JK.

Eur Neuropsychopharmacol. 2008 Feb;18(2):79-86. Epub 2007 Aug 14.

PMID:
17698328
18.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
19.

Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.

Greenhill LL, Newcorn JH, Gao H, Feldman PD.

J Am Acad Child Adolesc Psychiatry. 2007 May;46(5):566-72.

PMID:
17450047
20.

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.

Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM.

Psychopharmacology (Berl). 2007 Jan;190(1):31-41. Epub 2006 Nov 9.

PMID:
17093981
21.

Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder.

Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL.

J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):919-27.

PMID:
16865034
22.

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, Feldman PD, Levine LR.

J Pediatr. 2006 Jul;149(1):112-9.

PMID:
16860138
23.

Stabilization of the disk around beta Pictoris by extremely carbon-rich gas.

Roberge A, Feldman PD, Weinberger AJ, Deleuil M, Bouret JC.

Nature. 2006 Jun 8;441(7094):724-6.

PMID:
16760971
24.

Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.

Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ.

Neurology. 2005 Dec 27;65(12):1941-9.

PMID:
16380617
25.

Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.

Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH.

Clin Neuropharmacol. 2005 Sep-Oct;28(5):215-9.

PMID:
16239760
26.

Planetary science: the impact of Deep Impact.

Feldman PD.

Nature. 2005 Oct 13;437(7061):958-9. No abstract available.

PMID:
16222282
27.

Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.

Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, Lehman DL, Dossenbach M, Degenhardt EK, Breier A.

Am J Geriatr Psychiatry. 2005 Aug;13(8):722-30.

PMID:
16085789
28.

Atomoxetine and tics in ADHD.

Feldman PD, Ruff DD, Allen AJ.

J Am Acad Child Adolesc Psychiatry. 2005 May;44(5):405-6. No abstract available.

PMID:
15843758
29.

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.

Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR.

Br J Psychiatry. 2004 Apr;184:337-45.

PMID:
15056579
30.

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.

De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A.

Int J Geriatr Psychiatry. 2004 Feb;19(2):115-26.

PMID:
14758577
31.

Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.

Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, Hardy TA, Hoffmann VP, Hornbuckle K, Breier A.

J Am Med Dir Assoc. 2004 Jan-Feb;5(1):38-46.

PMID:
14706127
32.

A large population of 'Lyman-break' galaxies in a protocluster at redshift z approximately 4.1.

Miley GK, Overzier RA, Tsvetanov ZI, Bouwens RJ, Benítez N, Blakeslee JP, Ford HC, Illingworth GD, Postman M, Rosati P, Clampin M, Hartig GF, Zirm AW, Röttgering HJ, Venemans BP, Ardila DR, Bartko F, Broadhurst TJ, Brown RA, Burrows CJ, Cheng ES, Cross NJ, De Breuck C, Feldman PD, Franx M, Golimowski DA, Gronwall C, Infante L, Martel AR, Menanteau F, Meurer GR, Sirianni M, Kimble RA, Krist JE, Sparks WB, Tran HD, White RL, Zheng W.

Nature. 2004 Jan 1;427(6969):47-50.

PMID:
14702079
33.

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.

Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, Füredi J, Bartko G, Janka Z, Banki CM, Kovacs G, Breier A; Olanzapine HGCK Study Group.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):173-80.

PMID:
14687871
34.

Doubly ionized carbon observed in the plasma tail of comet Kudo-Fujikawa.

Povich MS, Raymond JC, Jones GH, Uzzo M, Ko YK, Feldman PD, Smith PL, Marsden BG, Woods TN.

Science. 2003 Dec 12;302(5652):1949-52.

35.

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

Feldman PD, Kaiser CJ, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A.

J Clin Psychiatry. 2003 Sep;64(9):998-1004.

PMID:
14628974
36.

Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling.

Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, Calabrese JR, Feldman PD, Jacobs TG, Breier A.

J Affect Disord. 2003 Jan;73(1-2):155-61.

PMID:
12507748
37.

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH.

Biol Psychiatry. 2002 Sep 1;52(5):438-45.

PMID:
12242060
38.

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Mintzer JE, Beckett LM, Breier A.

Neuropsychopharmacology. 2002 Apr;26(4):494-504.

39.

Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.

Tohen M, Zhang F, Keck PE, Feldman PD, Risser RC, Tran PV, Breier A.

J Affect Disord. 2001 Dec;67(1-3):133-40.

PMID:
11869760
40.

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.

Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A.

Arch Gen Psychiatry. 2002 Jan;59(1):62-9.

PMID:
11779284
41.

Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.

Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, Breier A.

Int J Geriatr Psychiatry. 2001 Dec;16 Suppl 1:S62-70.

PMID:
11748789
42.

Detection of molecular hydrogen in the atmosphere of Mars.

Krasnopolsky VA, Feldman PD.

Science. 2001 Nov 30;294(5548):1914-7.

43.

A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.

Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM.

J Child Adolesc Psychopharmacol. 2001 Fall;11(3):239-50.

PMID:
11642474
44.

Deficiency of molecular hydrogen in the disk of beta Pictoris.

Lecavelier des Etangs A, Vidal-Madjar A, Roberge A, Feldman PD, Deleuil M, André M, Blair WP, Bouret JC, Désert JM, Ferlet R, Friedman S, Hébrard G, Lemoine M, Moos HW.

Nature. 2001 Aug 16;412(6848):706-8.

PMID:
11507632
45.

HST and VLT investigations of the fragments of comet C/1999 S4 (LINEAR).

Weaver HA, Sekanina Z, Toth I, Delahodde CE, Hainaut OR, Lamy PL, Bauer JM, A'Hearn MF, Arpigny C, Combi MR, Davies JK, Feldman PD, Festou MC, Hook R, Jorda L, Keesey MS, Lisse CM, Marsden BG, Meech KJ, Tozzi GP, West R.

Science. 2001 May 18;292(5520):1329-33.

46.

Onset of action of antipsychotics in the treatment of mania.

Tohen M, Jacobs TG, Feldman PD.

Bipolar Disord. 2000 Sep;2(3 Pt 2):261-8. Review.

PMID:
11249804
47.

The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.

Clark WS, Street JS, Feldman PD, Breier A.

J Clin Psychiatry. 2001 Jan;62(1):34-40.

PMID:
11235926
48.

A novel augmentation strategy for treating resistant major depression.

Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY.

Am J Psychiatry. 2001 Jan;158(1):131-4.

PMID:
11136647
49.

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.

Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A.

Arch Gen Psychiatry. 2000 Oct;57(10):968-76.

PMID:
11015815
50.

Far-ultraviolet imaging spectroscopy of Io's atmosphere with HST/STIS.

Roesler FL, Moos HW, Oliversen RJ, Woodward RC Jr, Retherford KD, Scherb F, McGrath MA, Smyth WH, Feldman PD, Strobel DF.

Science. 1999 Jan 15;283(5400):353-7.

Supplemental Content

Loading ...
Support Center